osilodrostat   Click here for help

GtoPdb Ligand ID: 8310

Synonyms: Isturisa® | LCI-699 | LCI699
Approved drug PDB Ligand
osilodrostat is an approved drug (EMA & FDA (2020))
Compound class: Synthetic organic
Comment: Osilodrostat was designed as an inhibitor of aldosterone synthase (CYP11B2), but is also reported to inhibit the closely related enzyme, 11-beta-hydroxylase (CYP11B1) and hence as an inhibitor of cortisol biosynthesis [8]. It is this latter action of osilodrostat that is harnessed for clinical utility in Cushing's disease. The drug is orally bioavailable.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

osilodrostat is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 1
Topological polar surface area 41.61
Molecular weight 227.09
XLogP 2.18
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES N#Cc1ccc(c(c1)F)C1CCc2n1cnc2
Isomeric SMILES N#Cc1ccc(c(c1)F)[C@H]1CCc2n1cnc2
InChI InChI=1S/C13H10FN3/c14-12-5-9(6-15)1-3-11(12)13-4-2-10-7-16-8-17(10)13/h1,3,5,7-8,13H,2,4H2/t13-/m1/s1
InChI Key USUZGMWDZDXMDG-CYBMUJFWSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Clinical efficacy of osilodrostat as a treatment for Cushing's disease (CD) was evaluated in Phase 3 clinical trial NCT02697734 [5]. The EMA granted osilodrostat orphan drug designation for the treatment of CD in late 2014 and granted full marketing authorisation for this indication in January 2020 [4]. The FDA's approval followed in March 2020.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
As a treatment for CD, osilodrostat's action as an inhibitor of CYP11B1, the enzyme responsible for the synthesis of cortisol from 11-deoxycortisol, is clinically effective [3,6]. Osilodrostat's inhibitory effect on CYP11B2 has been investigated as a therapy for controlling hypertension as inhibiting CYP11B2 reduces the synthesis of aldosterone [1-2,7], a key hormone in the renin-angiotensin-aldosterone system (RAAS) which regulates blood pressure and fluid balance.
Additional experimental CYP11B2 inhibitors with improved selectivity are described in [8].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02697734 Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease Phase 3 Interventional Novartis